Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden

Haematologica

Volumn 96, Issue 3, 2011, Pages 18-20

  Zalcberg, Ilana Renault ^a   Ayres Silva, Jackline ^a   de Azevedo, Alexandre Mello ^b   Solza, Cristiana ^b   Daumas, Adelmo ^c   Bonamino, Martin ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Allele burden; Essential thrombocythemia; Hydroxyurea; JAK2 V617F; Polycythemia vera

Indexed keywords

GENOMIC DNA; HYDROXYUREA; JANUS KINASE 2;

ACUTE LEUKEMIA; ALLELE; DRUG USE; GRANULOCYTE; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HUMAN; LETTER; MYELOPROLIFERATIVE DISORDER; PLASMID; POLYCYTHEMIA VERA; THROMBOCYTE COUNT; THROMBOCYTHEMIA; WILD TYPE;

ALLELES; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE FREQUENCY; GRANULOCYTES; HEMATOLOGIC TESTS; HUMANS; HYDROXYUREA; JANUS KINASE 2; POINT MUTATION; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; THROMBOCYTHEMIA, ESSENTIAL;

EID: 79952330268     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.037846     Document Type: Letter

References (8)

1. Antonioli E, Carobbio A, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F, et al. Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica. 2010;95(8):1435-8.
2. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106(6):2162-8.
3. Xavier SG, Gadelha T, Pimenta G, Eugenio AM, Ribeiro DD, Gomes FM, et al. JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci. 2010; 55(6):1770-7.
4. Theocharides A, Passweg JR, Medinger M, Looser R, Li S, Hao-Shen H, et al. The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008; 93(12):1890-3.
5. Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Santos FD, et al. Frequent reduction or absence of detection of the JAK2- mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica. 2008; (11):1723-7.
6. Larsen TS, Pallisgaard N, de Stricker K, Møller MB, Hasselbalch HC. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Hematology. 2009;14(1):11-5.
7. Ricksten A, Palmqvist L, Johansson P, Andreasson B. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica 2008;93(8):1260-1.
8. S. Therapeutic potential of JAK2 inhibitors. Hematology Am Soc Hematol Educ Program. 2009:636-42.